Monthly Archives: June 2015

This condition long-term long-term complications such as cardiovascular diseases

Many ESRD and dialysis patients are in a state of chronic inflammation caused by the dialysis process the to further improve oxidative stress . This condition long-term long-term complications such as cardiovascular diseases, malnutrition, poor results and low survival rate. It is important to prevent reactive oxygen species production by improving the biocompatibility of the hemodialysis, says Dr. Jean-Paul Cristol, corresponding author. Antioxidant supplementation and ROS modulation by specific or non-specific drugs such as statins, are possible solutions described in the article. Correction of OS imbalance seems to be a basic requirement complications of complications in long-term dialysis patients and is a promising avenue of research. .

Oxidative stress, an imbalance between toxic compounds and defense mechanisms, and widely used in dialysis , has been to numerous adverse complications in end-stage renal disease patients combined. This by the overproduction by the overproduction of reactive oxygen species , or toxic compounds, and lack of antioxidants to fight these toxins. In fact, the process of hemodialysis in a loss of the necessary these antioxidants. Continue reading

Astellas Pharma U.

The addition of this vial size increases the convenience of use when administering MYCAMINE while. The waste reduction at the hospital – Astellas is to the doctors physicians with clinical opportunities to appropriate treatment decisions for their patients committed, said Richard White, Vice President, Critical Care at Astellas Pharma U.S. Said, The addition of the 100mg MYCAMINE vial provides physicians with a convenient possibility is that the waste in the clinical setting can be reduced.. Astellas Pharma U.S., announced the availability of MYCAMINE 100 mg vialAstellas Pharma U.S., announced today the availability of their antifungal agent MYCAMINE for injection in a 100mg vial format.

Isolated cases of clinically significant hepatic dysfunction, hepatitis, worsening hepatic failure, renal dysfunction, acute renal failure have, U.S. Subsidiary in some patients who received MYCAMINE occurred. Patients should develop these conditions, or abnormal liver or kidney function tests for the degradation and evaluated. And evaluated. For the risk / benefit of continuing MYCAMINE therapy. Continue reading

About geographic atrophy geographic atrophy is the advanced form of atrophic AMD.

About geographic atrophy geographic atrophy is the advanced form of atrophic AMD. According to data published in Archives of Ophthalmology approximately 973,000 people in the U.S. Had GA in at least one eye on 2004. This figure is more than 50 more than 50 percent by 2020. Currently, there are no therapeutic treatment for GA.

Sirion Therapeutics Initiates Enrollment Of Phase II clinical trial for the treatment of geographic atrophySirion Therapeutics, an ophthalmic-focused biopharmaceutical company, announced today that it commenced enrollment of a Phase II clinical study evaluating fenretinide in the treatment of geographic atrophy in patients with age-related macular degeneration. Continue reading

Page 5 of 512345